A monoclonal antibody as an effective therapeutic agent in breast cancer: Trastuzumab

Expert Opinion on Biological Therapy

Volumn 5, Issue 6, 2005, Pages 853-866

  Rueckert, S ^a   Ruehl, I ^a   Kahlert, S ^a   Konecny, G ^b   Untch, M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anthracycline; Capecitabine; Cardiotoxicity; Combination chemotherapy; Fish; Gemcitabine; HER 2 neu; Humanised monoclonal antibody; IHC; Monotherapy; Platinum salts; Small molecule inhibitor; Taxane; Trastuzumab; Vinorelbine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GEMCITABINE; LETROZOLE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TAMOXIFEN; TRASTUZUMAB;

ABDOMINAL PAIN; ADULT RESPIRATORY DISTRESS SYNDROME; ALOPECIA; ANAPHYLAXIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; ARTHRALGIA; ASTHENIA; BACKACHE; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST CARCINOMA; BRONCHOSPASM; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEVER; FLU LIKE SYNDROME; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEADACHE; HEART FUNCTION; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXIA; IMMUNOHISTOCHEMISTRY; INFECTION; INJECTION SITE REACTION; INSOMNIA; LEUKOPENIA; LUNG EDEMA; LUNG INFILTRATE; LUNG INSUFFICIENCY; METASTASIS; MONOTHERAPY; MYALGIA; NAUSEA; PAIN; PARESTHESIA; PHARYNGITIS; PLEURA EFFUSION; PRURITUS; RASH; RESPIRATORY DISTRESS; REVIEW; RHINITIS; STOMATITIS; TACHYCARDIA; THORAX PAIN; TREATMENT OUTCOME; WHEEZING;

ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; FEMALE; HEART DISEASES; HUMANS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, ERBB-2; TAXOIDS; VINBLASTINE;

EID: 21044457518     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.6.853     Document Type: Review

References (80)

1. AMERICAN CANCER SOCIETY: Cancer Facts and Figures 2004. American Cancer Society, Atlanta, GA, USA (2004).
2. COUSSENS L, YANG-FENG TL, LIAO YC et al.: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (1985) 230:1132-1139.
3. KING CR, KRAUS MH, AARONSON SA: Amplification of a novel v-erbB related gene in human mammary carcinoma. Science (1985) 229:974-976.
4. SHIH C, PADHY LC, MURRAY M, WEINBERG RA: Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature (1981) 290:261-264.
5. rd, CANTLEY LC: A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell (1994) 78(1):5-8.
6. ABDEL-REHIM DM, PINDER SE, PAISH CE et al.: Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br. J. Cancer (2004) 91(8):1532-1542.
7. WEN D, PELES E, CUPPLES R et al.: Neu differentiation factor: a transmembrane glycoprotein containing and EGF domain and an immunoglobulin homology unit. Cell (1992) 69:559-572.
8. SLAMON DJ, CLARK GM, WONG SG, LEVIN WJ, ULLRICH A, MCGUIRE WL: Human Breast cancer: correlation of relapse and survival with amplificationon HER-2/neu oncogene. Science (1987) 235:177-182.
9. SLAMON DJ, GODOLPHIN W, JONES LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244:707-712.
10. ROSS JS, FLETCHER JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells (1998) 16:413-428.
11. SESHADRI R, FIRGAIRA FA, HORSFALL DJ, MCCAUL K, SETLUR V, KITCHEN P: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J. Clin. Oncol. (1993) 10:1936-1942.
12. FENDLY BM, WINGET M, HUDZIAK RM, LIPARI MT, NAPIER MA, ULLRICH A: Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER-2/neu gene product: Cancer Res. (1990) 50:1550-1158.
13. CARTER P, PRESTA L, GORMAN CM et al.: Humanization of an anti-p185HER-2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA (1992) 89:4285-4289.
14. BASELGA J, ALBANELL J, MOLINA MA, ARRIBAS J: Mechansim of action of trastuzumab and scientific update. Semin. Oncol. (2001) 28(5 Suppl. 16):4-11.
15. PETIT AM, RAK J, HUNG MC et al.: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. (1997) 151:1523-1530.
16. KONECNY G, PEGRAM M, BERYT M, UNTCH M, SLAMON DJ: Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression. Breast Cancer Res. Treat. (1999) 57:114 (Abstract 467).
17. PEGRAM M, HSU S, LEWIS G et al.: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancer. Oncogene (1999) 18:2241-2251.
18. PEGRAM MD, KONECNY GE, O'CALLAGHAN C, BERYT M, PIETRAS R, SLAMON DJ: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl. Cancer Inst. (2004) 96(10):739-749.
19. WITTERS LM, KUMAR R, CHINCHILLI VM et al.: Enhanced antiproliferative activity of the combination of tamoxifen plus Her2-neu antibody. Breast Cancer Res. Treat. (1997) 42:1-5.
20. KUNISUE H, KUREBAYASHI J, OTSUKI T et al.: Anti-HER2 antibody enhances the growth inhibitor effect of antioestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br. J. Cancer (2000) 82:46-51.
21. GENENTECH, INC./ F. HOFFMANN-LA ROCHE LTD: Investigator Brochure: Herceptin®-Genentech, Inc./ F. Hoffmann-La Roche Ltd (2004).
22. GENENTECH, INC.: Herceptin®: Manufacturer's prescribing information, Fachinformation (German) (2004).
23. TOKUDA Y, WATANABE T, OMURO Y et al.: Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br. J. Cancer (1999) 81(8):1419-1425.
24. GEMON K, ARNOLD A, VERMA S et al.: Pharmacokinetics and safety of trastuzumab when administered every three weeks to women with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (2001) 19:69a (Abstract 271).
25. PESTALOZZI BC, BRIGNOLI S: Herceptin® (trastuzumab) in cerebrospinal fluid. Eur. J. Cancer (2000) 36(Suppl. 5):54.
26. COBLEIGH MA, VOGEL CL, TRIPATHY D et al.: Multinational study of the efficacy and safety of humanized ami-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. (1999) 17:2639-2648.
27. PEGRAM MD, LIPTON A, HAYES DF et al.: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. (1998) 16:2659-2671.
28. BASELGA J, TRIPATHY D, MENDELSOHN J et al.: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J. Clin. Oncol. (1996) 14:737-744.
29. VOGEL CL, COBLEIGH M, TRIPATHY D et al.: Efficacy and safety of trastuzumab as a single agent in first line treatment of HER2 overexpressing metastatic breast cancer. J. Clin. Oncol. (2002) 120:719-726.
30. SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 11:783-792.
31. FYFE GA, MASS R, MURPHY M et al.: Survival benefit of trastuzumab (Herceptin) and chemotherapy in older (age > 60) patients. Proc. Am. Soc. Clin. Oncol. (2001) 19:Absttact 189.
32. EXTRA JM, COGNETTI F, MARANINCHI D et al.: Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positve metastatic breast cancer (MBC): results of a randomized multicentre trial. Eur. J. Cancer Suppl. (2004) 2:Abstract 239.
33. SEIDMAN AD, FORNIER MN, ESTEVA FJ et al.: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by Her-2 immunophenotype and gene amplification. J. Clin. Oncol. (2001) 19(10):2587-2595.
34. ESTEVA FJ, VACERO V, BOOSER D et al.: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol. (2002) 20:1800-1808.
35. UNTCH M, EIDTMANN H, DU BOIS A et al.: Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a Phase I trial. Eur. J. Cancer (2004) 40(7):988-997.
36. THEODOULOU M, HUDIS C: Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer (2004) 100(10):2052-2063.
37. THEODOULOU M, CAMPOS S, BATIST G et al.: TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cacner (ABC): final cardiac safety and efficacy analyis. Proc. Am. Soc. Clin. Oncol. (2002) 20:55a (Abstract 216).
38. CHIASK, CLEMONS M, MARTIN LA et al.: A multi-centre Phase II trial of pegylated liposomal doxorubicin and trastuzumab in HER-2 over-expressing metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. (2004) 22:Abstract 630.
39. BURSTEIN HJ, KUTER I, CAMPOS SM et al.: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. (2001) 19:2722-2730.
40. BURSTEIN HJ, HARRIS LN, MARCOM K et al.: Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter Phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J. Clin. Oncol. (2003) 21:2889-2895.
41. JAHANZEB M, MORTIMER JE, YUNUS F et al.: Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer. Oncologist (2002) 7:410-117.
42. BANGEMANN N, KUHLE A, WILLRODT RG, BUEHLER H, SCHALLER G: Treatment of HER2 overexpressing metastatic breast cancer (MBC) with trastuzumab (Herceptin) and chemotherapy. Breast Cancer Res. Treat. (2000) 64:123 (Abstract 530).
43. BANGEMANN N, KUHLE A, EBERT A, BUHLER H, SCHALLER G: Capecitabine combined with trastuzumab in the therapy pf intensively pretreated HER-2 overexpressing metastatic breast cancer (MBC). Ann. Oncol. (2000) 11 (Suppl. 4): 143 (Abstract 143).
44. BRUFSKY A, ORLANDO M, FOX K et al.: Phase II study of gemcitabine (Gem) and trastuzumab (T) combination therapy in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC). First stage results. San Antonio Breast Cancer Symposium (2004) 27:Abstract 3047.
45. SLEDGE GW JR: Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Huntingt). (2003) 17(12 Suppl. 14):33-35.
46. O'SHAUGHNESSY JA, VUKELJA S, MARSLAND T, KIMMEL G, RATNAM S, PIPPEN JE: Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin. Breast Cancer (2004) 5(2):142-147.
47. PEGRAM MD, PIENKOWSKI T, NORTHFELT DW et al.: Results of two open-label, multicenter Phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J. Natl. Cancer Inst. (2004) 96(10):759-769.
48. PEREZ EA, ROWLAND KM, SUMAN VJ et al.: N98-32-52: efficacy and tolerability of two schedules of paclitaxel, carboplatin and trastuzumab in women with HER2 positive metastatic breast cancer: a North Central Cancer Treatment Group randomized Phase II trial. San Antonio Breast Cancer Symposium (2003) 26:Abstract 216.
49. ROBERT NJ, LEYLAND-JONES B, ASMAR L et al.: Randomized Phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: an update including survival. Proc. Am. Soc. Clin. Oncol. (2004) 22:Abstract 573.
50. DOWSETT M: Overexpression of Her-2 as a resistance mechanism to hormonal therapy in breast cancer. Endocr. Relat. Cancer (2001) 8:191-195.
51. LIPTONA, ALI SM, LEITZEL K et al.: Elevated HER-2/neu level predicts decreased response to hormonal therapy in metastatic breast cancer. J. Clin. Oncol. (2002) 20:1467-1472.
52. BORG A, BALDETORP B, FERNO M et al.: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. (1994) 81(2):137-144.
53. KONECNY G, PAULETTI G, PEGRAM M et al.: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J. Natl. Cancer Inst. (2003) 95(2):142-153.
54. ELLlS MJ, COOP A, SINGH B et al.: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J. Clin. Oncol. (2001) 19(18):3808-3816.
55. ROMOND EH, PEREZ E, BRYANT J et al.: Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer. Combined analysis of NSABP-B31/ NCCTG-N9831. Proceedings from the 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA (May 2005).
56. PEREZ EA, SUMAN VJ, DAVIDSON N, MARTINO S, KAUFMAN P: NCCTG N9831. Proceedings from the 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA (May 2005).
57. PICCART-GEBHART JM: First results of the HERA trial. Proceedings from the 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA (May 2005).
58. BUZDAR AU, HUNT K, SMITH T et al.: Significantly higher pathological complete remission (PCR)rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): initial results of a randomized trail in operable breast cancer (BC) with Her/2 positive disease. Proc. Am. Soc. Clin. Oncol. (2004) 22:Abstract 520.
59. BURSTEIN HJ, HARRIS LN, GELMAN R et al.: Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for Her2 overexpressing stage II or III breast cancer: a pilot study. J. Clin. Oncol. (2003) 21(1):46-53.
60. CAREY LA, DEES EC, SAWYER L et al.: Response to trastuzumab (Herceptin) given with paclitaxel (taxol, T) immediately following 4 AC as initial therapy for primary breast cancer (BrCA). Breast Cancer Res. Treat. (2002) 76:Abstract 424.
61. HARRIS L, BURSTEIN HJ, GELMAN R et al.: Preoperative trastuzumab and vinorelbine (HN) is a highly active, well-tolerated regimen for HER2 3+/FISH + stage II/III breast cancer. Proc. Am. Soc. Clin. Oncol. (2003) 21:Abstract 86.
62. HURLEY J, DOLINY P, SILVA O et al.: Neoadjuvant herceptin/taxotere/ cisplatin in the treatment of locally advanced and inflammatory breast cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:Abstract 196.
63. MASS RD, PRESS M, ANDERSON S et al.: Improved survival benefit from Herceptin (trastuzumab) in patients selects by fluorescence in situ hybridization (FISH). Proc. Am. Soc. Clin. Oncol. (2001) 19:Abstract 85.
64. PAULETTI G, DANDEKAR S, RONG H et al.: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J. Clin. Oncol. (2000) 18:3651-3664.
65. HOFMANN M, GAISER T, KNEITZ H et al.: HER2 status assessment by chromogenic in-situ hybridization (CISH) demonstrates high sensitivity for predicting response to Herceptin®. San Antonio Breast Cancer Symposium (2004) 27:Absrract 1037.
66. MÜLLER V, THOMSSEN C, KARAKAS C et al.: Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay. Int. J. Biol. Markers (2003) 18(1):13-20.
67. HAYES DF, YAMAUCHI H, BROADWATER G et al.: Circulating Her-2/erbB-2/neu (Her-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin. Cancer Res. (2001) 7:2703-2711.
68. MEHTA RR, MCDERMOTT JH, HIEKEN TJ et al.: Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. J. Clin. Oncol. (1998) 16(7):2409-2416.
69. LEYLAND-JONES B, GELMON K, AYOUB JP et al.: Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J. Clin. Oncol. (2003) 21(21):3965-3971.
70. CASTELLON XC, CASTENADA-SOTA NJ, CLEMENS M et al.: Efficacy and safety of 3-weekly Herceptin monotherapy in women with HER2 positive metastatic breast cancer. Preliminary data from a Phase II study. Proc. Am. Soc. Clin. Oncol. (2002) 20:Abstract 73.
71. FOUNTZILAS G, RAZIS E, TSAVDARIDIS D et al.: Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer. A retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin. Breast Cancer (2003) 4(2):120-125.
72. SEIDMAN A, HUDIS C, PIERRI MK et al.: Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. (2002) 20(5):1215-1221.
73. SUTER TM, COOK-BRUNS N, BARTON C: Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast (2004) 13:173-183.
74. MARTY M, BASELGA J, GATZEMEIER U et al.: Polled analysis of six trials of trastuzumab (Herceptin®): exploratory analysis of changes in left ventricular ejection fraction (LVEF) as a surrogate for clinical cardiac events. San Antonio Breast Cancer Symposium (2003) 26:Abstract 218.
75. LEE KF, SIMON H, CHEN H et al.: Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature (1995) 378:394-398.
76. ÖZCELIK C, ERDMANN B, PILZ B et al.: Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl. Acad. Sci. USA (2002) 99(13):8880-8885.
77. CRONE SA, ZHAO YY, FAN L et al.: ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. (2002) 8:459-465.
78. BRITTEN CD, PEGRAM M, ROSEN P et al.: Targeting ErbB receptor interactions: a Phase I trial of trastuzumab and erlotinib in metastatic HER2+breast cancer. Proc. Am. Soc. Clin. Oncol. (2004) 22:Abstract 3045.
79. BURRIS HA III, STORNIOLO AM, OVERMOYER EA et al.: A Phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. San Antonio Breast Cancer Symposium (2004) 27:Abstract 3043.
80. ARTEAGA CL, O'NEIL A, MOULDER SL et al.: ECOG1100: a Phase I-II study of combined blockade of the erbB receptor network with trastuzumab and gefitinib ([Isquo]Iressa) in patients (pts) with HER2-overexpressing metastatic breast cancer (met br ca). San Antonio Breast Cancer Symposium (2004) 27:Abstract 25.